Original research

Defective Neutrophil Function in Patients with Sepsis is Mostly Restored by ex vivo Ascorbate Incubation

Kritsanawan Sae-khow[1], Sasipha Tachaboon[2], Helen L Wright[3], Steven W Edwards[4], Nattachai Srisawat[2], Asada Leelahavanichkul[1], Direkrit Chiewchengchol[1]

[1]Translational Research in Inflammation and Immunology Research Unit, Faculty of Medicine, Chulalongkorn University; [2]Excellence center for critical care nephrology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; [3]Institute of Ageing and Chronic Disease and [4]Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom

Corresponding author:

Direkrit Chiewchengchol, MD, PhD

E-mail: *cdirekrit@live.com*

Word count for text: 3,842

Word count for Abstract: 281

Figures: 4 Supplement figures: 2 Table: 1 Supplement Table: 1

References: 59

Abstract

Background: Neutrophil function is essential for effective defence against bacterial infections but is defective in patients with sepsis. Ascorbate or vitamin C, which is low in the plasma of patients with sepsis, is stored inside human neutrophils and is essential for their normal function.

Objectives: This study aimed to determine if ascorbate treatment *ex vivo* improved neutrophil function in patients with sepsis.

Methods: Human blood neutrophils were isolated from 20 patients with sepsis and 20 healthy age-matched controls. Neutrophils were incubated with or without ascorbate (1, 5, 10, 20 and 40 mM) for periods up to 2h. Chemotaxis was evaluated using a chemotactic chamber in response to the chemoattractant, fMLP. Phagocytosis (uptake of pHrodo red stained *S.aureus*) and apoptosis (annexin-V/propidium iodide staining) were measured by flow cytometry. Neutrophil extracellular trap (NET) formation was detected and quantified using DAPI, anti-myeloperoxidase and anti-neutrophil elastase immuno-fluorescence staining. Quantifluor detected the amount of dsDNA in NET supernatants, while quantitative PCR identified changes in expression of *PADI4* gene.

Results: Chemotatic and phagocytic activities were decreased in patients with sepsis but increased after treatment with high concentrations of ascorbate. Apoptosis was increased in the sepsis patients but not altered by ascorbate treatment. Spontaneous NET formation was observed in patients with sepsis. 1mM ascorbate decreased spontaneous NETosis to that of normal, healthy neutrophils, while high concentrations of ascorbate (> 10mM) further promoted NET formation.

Conclusion: Dysregulated neutrophil function was observed in patients with sepsis which could contribute to disease pathology and outcomes. Exposure to ascorbate could reverse some of these changes in function. These novel discoveries raise the

possibility that ascorbate treatment could be used as an adjunctive therapy that could result in improved neutrophil function during sepsis.

Plain language summary

- Decreased neutrophil chemotaxis and phagocytosis were observed in patients with sepsis but this was improved by high concentrations of ascorbate.
- Patients with sepsis showed an increase in neutrophil apoptosis which did not change after ascorbate treatment.
- Patients with sepsis underwent high rates of spontaneous NETosis, that was decreased by 1mM of ascorbate treatment.

Keywords: ascorbate, neutrophils, sepsis

1. Introduction

Neutrophils are the most abundant type of white blood cell in human circulation and their main function is to protect against invading pathogens by a variety of mechanisms such as chemotaxis, phagocytosis, apoptosis and neutrophil extracellular trap (NET) formation.[1,2] There are several factors that maintain the effectiveness of neutrophil function, one of which is ascorbate or vitamin C.[3-7] Ascorbate, a water-soluble vitamin, is essential for human homeostasis, metabolism and function of the immune system and is stored inside cytoplasm of neutrophils via vitamin C transporters.[8-10] Although it has been reported that ascorbate promotes neutrophil chemotaxis and phagocytosis,[3,4,11] its effects on NET formation and apoptosis are not well studied.[5,7,12] In addition, it is unknown if ascorbate deficiencies or ascorbate supplementation can contribute to neutrophil function in inflammatory

52 conditions or during infections such as sepsis, where neutrophil function may be
53 compromised.

54 Although neutrophils are normally highly-effective in eliminating invading
55 pathogens, sometimes the invasion of pathogenic organisms overcomes this defence
56 system, leading to systemic infection and sepsis.[1,2,13,14] Sepsis is a life-threatening
57 condition when the immune system, particularly neutrophils, vigorously battle against
58 systemic infection. However, it has been reported that defective neutrophil function is
59 observed in patients during sepsis, particularly elderly people with underlying
60 illnesses and patients who are immune-compromised (eg those with diabetes, heart
61 diseases or malignancies).[15]

62 As ascorbate is an essential factor for neutrophil function, this study
63 determined whether ascorbate treatment *ex vivo* enhanced neutrophil function in
64 patients with sepsis. Neutrophil chemotaxis, phagocytosis, apoptosis and NET
65 formation, including peptidyl arginine deiminase 4 or *PADI4* gene expression
66 (essential for the process of NET formation), were investigated *in vitro*. Here, we
67 make the novel observation that short term (2h) ascorbate treatment can enhance
68 several neutrophil functions that were impaired in the sepsis patients. These novel
69 observations raise the possibility that ascorbate treatment might be a useful adjunct
70 therapy for sepsis patients.

71

72 **2. Materials and Methods**

73 The following reagents were used in this study: Polymorphprep (Axis-Shield,
74 Norway); RPMI 1640 media with 25mM HEPES, L-Glutamine (Hyclone, USA); fetal
75 bovine serum (Gibco, USA); sodium L-ascorbate (Sigma, USA); rabbit anti-
76 neutrophil elastase and mouse anti-myeloperoxidase and Alexa Fluor 488 conjugated
77 goat anti-rabbit IgG and Alexa Fluor 647 conjugated anti-mouse IgG (Abcam, UK);

78 4’,6-Diamidino-2-phenylindole dihydrochloride (Merck, USA); micrococcal nuclease
79 from *S. aureus* (Sigma, USA); QuantiFluor one dsDNA (picogreen), (Promega,
80 USA); Trizol^{TM} Reagent (Ambion, USA); iScript^{TM} RT supermix; SsoAdvanced^{TM}
81 Universal SYBR Green Supermix (BIO-RAD, USA); *PADI4* PCR primers (forward:
82 5'-CGAAGACCCCCAAGGACT-3', reverse: 5'-AGGACAGTTTGCCCCGTG-3')
83 and *ITGB2* PCR primers (forward: 5'-GCTGTCCCCACAAAAAGTG-3', reverse: 5'-
84 CCGGAAGGTCACGTTGAA-3') and β-actin PCR primers (forward: 5'-TTCCTG
85 GGCATGGAGTC-3', reverse: 5'-CAGGTCTTTGCGGATGTC-3') (Integrated DNA
86 Technology, Singapore); fMLP and Millipore Hanging Cell Culture plate inserts
87 (MERCK, USA); Trypan blue (Sigma, USA); Annexin V-APC and propidium iodide
88 (Biolegend, USA); pHrodo^{TM} Red *S. aureus* Bioparticles Phagocytosis Kits
89 (Invitrogen, USA).

90 **2.1 Patient and healthy controls**

91 Twenty patients diagnosed with sepsis using Sepsis-3 criteria,[16-19] who
92 attended the Emergency Department, Intensive Care Unit or Intermediate Intensive
93 Care Unit, Inpatient Department, and 20 healthy aged-match controls were randomly
94 recruited from the King Chulalongkorn Memorial Hospital, Thailand. Table 1
95 presents the demographics, underlying illnesses and identified organisms in
96 hemoculture specimens in the patients. The levels of ascorbate (vitamin C) in plasma
97 from patients with sepsis and healthy controls were measured using High
98 Performance Liquid Chromatography (HPLC, Chromosystem, Germany) and shown
99 in Table 1. Other detailed information of patients diagnosed with sepsis including
100 blood chemistry, blood coagulation status, platelet count, source of infection and
101 Sequential Sepsis-Related Organ Failure Assessment (SOFA) score, was presented in
102 Supplementary Table 1. This study was approved by Chulalongkorn University
103 Human Research Ethic Committee (IRB 113/60) with validity date from 18 May 2018

104 until 17 May 2019. Written informed consent and/or assent forms were obtained from
105 all donors.

106 **2.2 Isolation of Neutrophils**

107 The blood samples were collected within 72h after the patients had been
108 diagnosed with sepsis. Neutrophil isolation and culture method was described in our
109 previous studies.[20,21] In brief, neutrophils were isolated from heparinised peripheral
110 blood of patients with sepsis and healthy donors using Polymorphprep, according to
111 the manufacturer's instructions. Red blood cell contamination was removed by
112 hypotonic lysis buffer. Neutrophils were re-suspended in RPMI 1640 media and the
113 purity was assessed by staining with Wright stain and was > 95%. Re-suspended
114 neutrophils were incubated at 37°C in a 5% CO_2 incubator, with or without 10% (v/v)
115 fetal bovine serum, as indicated in the text.

116 **2.3 Neutrophil chemotaxis assay**

117 The chemotaxis assay was performed using 24-well tissue culture plates.
118 Isolated neutrophils were treated with or without different concentrations of ascorbate
119 for 2h in a 5% CO_2 incubator. Chemoattractant (fMLP) was added into the wells, and
120 the hanging inserts with a 3 μm pore-size filter were suspended in the culture media.
121 Neutrophils at 10^6 cells/mL were added into the hanging inserts and incubated for 90
122 min at 37°C in a 5% CO_2 incubator. The hanging inserts were then removed and
123 migrated neutrophils in each well were counted using the Countess™ II automated
124 cell counter (Thermo Fisher Scientific). Trypan blue staining was performed for
125 detection of viable cells.

126 **2.4 Neutrophil phagocytosis**

127 Phagocytic activity was measured using pHrodo™ Red *S. aureus* Bioparticles
128 Phagocytosis Kits.[22] Isolated neutrophils were treated with or without different
129 concentrations of ascorbate for 2h at 37°C in a 5% CO_2 incubator. The cells were

130 incubated with Bioparticles for 30min in the incubator. The cells were washed and
131 resuspended with PBS. Neutrophil phagocytosis was analysed on a flow cytometer
132 (FACsAria II, BD Biosciences, USA) measuring 20,000 events per sample.

133 **2.5 Neutrophil apoptosis**

134 After 2h incubation in the presence or absence of different concentrations of
135 ascorbate, neutrophils at $2.5x10^4$ cells were stained with Annexin V-APC (10μL/mL)
136 for 15min before they were stained with propidium iodide (1μg/mL) as described
137 previously [23]. Stained cells were then analysed on a flow cytometer (FACsAria II, BD
138 Biosciences, USA) analysing 20,000 events per sample.

139 **2.6 Neutrophil extracellular trap (NET) assay**

140 Sterile round glass cover slips were placed into each well of a 24-well cell
141 culture plate. Neutrophils ($5x10^5$ cells) were added to each well and incubated for 1h
142 at 37°C in a 5% CO_2 incubator. Different concentrations of ascorbate (1, 5, 10, 20 and
143 40 mM) or 600nM phorbol myristate acetate (PMA) were added into the wells and
144 incubated for 2h. The culture media was gently aspirated and the cover slips were
145 washed with PBS. The cells and NETs were fixed with 1% formaldehyde. The glass
146 cover slips were removed and incubated with 0.05% Tween in 1xPBS at room
147 temperature for 1min to permeabilize the cells. The cells were blocked for 30min with
148 1xTBS with 2% bovine serum albumin.

149 NET formation was detected using immunofluorescence. Primary antibodies
150 (rabbit anti-Neutrophil Elastase and mouse anti-Myeloperoxidase) were added (at
151 1:100 dilution) and incubated for 30min at room temperature. After washing in
152 1xTBS, secondary antibodies (anti-rabbit IgG and anti-mouse IgG) were added (at
153 1:400 dilution) and incubated for further 30min. The cover slips were washed and
154 then stained with DAPI (1μg/mL) before NET identification using a fluorescence
155 microscope.[24] The number of NETing cell was counted per 100 cells.

156 **2.7 Quantification of NET formation (QuantiFlour®dsDNA)**

157 Neutrophils were incubated exactly as described in 2.3 (in the absence and
158 presence of ascorbate at the indicated concentrations) and incubated for 2h. After this
159 incubation period, 0.1 M $CaCl_2$ was added, followed by 500 mU of micrococcal
160 nuclease for 10min to digest the NET structure and fragment the DNA. EDTA (0.5
161 M) was added to inhibit the reaction and supernatants containing DNA were
162 collected. Quantifluor (PicoGreen) was added to the supernatants, according to the
163 manufacturer's instructions and incubated at room temperature for 5min in the dark.
164 The amount of DNA in the mixture was measured at 485 nm excitation (535 nm
165 emission) on a PROMEGA Quantus™ Fluorometer.[24]

166 **2.8 *PADI4* mRNA expression**

167 Total RNA from isolated neutrophils was extracted using Trizol™ Reagent
168 followed by a DNase digestion step, according to the manufacturer's instruction.[20]
169 The extracted RNA was converted to cDNA using iScript™ RT supermix. *PADI4*
170 gene expression was detected by quantitative PCR using SsoAdvanced™ Universal
171 SYBR Green Supermix (BIO-RAD),[25] using a 7500 ABI Real-Time PCR System.

172 **2.9 Statistical analysis**

173 Statistical analyses were performed by using GraphPad version 7, Student's t-
174 test and One-way ANOVA test. Data are expressed as mean ± SEM, and differences
175 with a p-value of <0.05 were considered statistically-significant.

176

177 **3. Results**

178 **3.1 Neutrophil chemotaxis, phagocytosis and apoptosis in patients with sepsis**

179 Neutrophils isolated from patients with sepsis showed significantly decreased
180 cell migration (13.6 ± 8.5%, n=10, p<0.01) in a response towards the chemoattractant
181 fMLP (100 nM), compared to healthy control neutrophils (31.3 ± 10.7%, n=10)

182 (Figure 1A and 1B). Phagocytic activity of neutrophils isolated from patients with
183 sepsis was significantly decreased (15.4 ± 2.6%, n=5, p<0.01), compared with healthy
184 controls, (34.4 ± 15.3%, n=5) (Figure 1C and 1D). Increased neutrophil apoptosis was
185 observed in patients with sepsis (15.6 ± 2.3%, n=5, p<0.005) compared to healthy
186 controls (7.3 ± 1.5%, n=5) when measured 2h post-isolation (Figure 1E and 1F).

187 **3.2 Spontaneous NET formation in patients with sepsis**

188 Neutrophils isolated from patients with sepsis showed significantly increased
189 capacity for spontaneous NET formation after 2h post-isolation (21.7 ± 18.7 cells/100
190 cells undergoing NETosis, n=20, p<0.001) compared to healthy control neutrophils
191 which showed only barely detectable levels of NETosis (1.2 ± 0.9 cells/100 cells,
192 n=20) (Figure 2A and 2B). Immuno-fluorescence staining confirmed the presence of
193 both elastase and myeloperoxidase on these DNA structures, confirming the
194 formation of genuine NETs (Figure 2A). Induced NET formation by PMA as a
195 positive control is shown in Supplementary Figure 1.

196 NETs contain double-stranded DNA (dsDNA),[26,27] and so we quantified the
197 amount of released dsDNA from sepsis patients and healthy donors. The results
198 showed that the levels of dsDNA were significantly increased in patients with sepsis
199 (0.94 ± 0.24 ng/mL, n=10, p<0.01) compared to healthy control neutrophils (0.63 ±
200 0.14 ng/mL, n=10) (Figure 2C). To confirm these observations, we measured mRNA
201 expression of *PADI4* gene as PAD4 enzyme is required for the process of NET
202 formation.[12,28] The results showed that *PADI4* mRNA expression was significantly
203 increased in patients with sepsis (7.6 ± 3.3, n=10, p<0.05), compared to healthy
204 control neutrophils (3.9 ± 2.2, n=10) (Figure 2D).

205 **3.3 Neutrophil chemotaxis, phagocytosis and apoptosis after ascorbate treatment**
206 **in patients with sepsis**

207 After 2h treatment with different concentrations of ascorbate, the percentages
208 of cell migration when neutrophils were treated with high concentrations (10, 20 and
209 40 mM) of ascorbate, were significantly increased in both sepsis patients (51.9 ±
210 10.8%, 67.7 ± 15.6% and 59.5 ± 9.9%, respectively) and healthy neutrophils (65.0 ±
211 6.7%, 77.5 ± 8.1%, and 75.1 ± 9.7 %, respectively), compared to sepsis and healthy
212 neutrophils (29.9 ± 11.0 % and 51.5 ± 11.4%, respectively, n=5 for both groups,
213 p<0.001) (Figure 3A). Of note, the increased rates of neutrophil chemotaxis in sepsis
214 patients and healthy controls were comparable at each concentration of ascorbate
215 (p>0.05), except only at 1 and 40 mM (p<0.01).
216 Ascorbate treatment increased neutrophil phagocytosis in sepsis patients but
217 this increase was significantly enhanced at a concentration of 40 mM (46.1 ± 19.8%,
218 n=5, p<0.01) when compared with untreated neutrophils (15.4 ± 2.6%, n=5) (Figure
219 3B). However, we did not observe an increase in phagocytosis from healthy control
220 neutrophils after ascorbate treatment (n=5, p>0.05). In addition, no significance
221 differences in neutrophil phagocytosis were found between sepsis patients and healthy
222 controls at each concentration of ascorbate treatment (p>0.05).
223 The percentages of neutrophil apoptosis in sepsis patients and healthy controls
224 were unaffected by 2h treatment with ascorbate at all concentrations tested (n=5 for
225 both groups, p>0.05) (Figure 3C). These percentages of neutrophil apoptosis were
226 still significantly increased in patients with sepsis compared with healthy controls at
227 every concentrations of ascorbate treatment (p<0.01).
228 **3.4 NET formation after ascorbate treatment in patients with sepsis**
229 After 2h treatment with different concentrations of ascorbate, the level of NET
230 formation from neutrophils incubated with 1 mM ascorbate was significantly lower
231 (4.4 ± 3.1 cells/100 cells, n=10, p<0.05) in patients with sepsis, compared to untreated
232 sepsis neutrophils (21.7 ± 18.7 cells/100 cells, n=10) (Figure 4A and 4B). However,

233 the levels of dsDNA and *PADI4* mRNA expression from sepsis neutrophils treated
234 with 1mM were decreased but these decreases did not reach statistical significances
235 (p>0.05) (Figure 4C and 4D). Furthermore, the levels of NET formation, dsDNA and
236 *PADI4* mRNA expression between sepsis patients and healthy controls were
237 comparable when their neutrophils were treated with 1 mM of ascorbate (Figure 4B,
238 4C and 4D) (p>0.05).

239 In contrast, higher levels of NET formation were observed in sepsis
240 neutrophils after ascorbate treatment (≥5 mM) particularly at the concentrations of 20
241 and 40 mM (42.3 ± 10.9 and 57.8 ± 17.4 NETs/100 cells, respectively, p<0.001),
242 compared to untreated sepsis neutrophils (21.7 ± 18.7 NETs/100 cells, n=20 for both
243 groups). This observation was also observed in healthy neutrophils after ascorbate
244 treatment (≥5 mM), compared to untreated healthy neutrophils (p<0.001) (Figure 4B).
245 The levels of NET formation expression between sepsis patients and healthy controls
246 were comparable at every concentrations of ascorbate treatment (p>0.05), except at 40
247 mM (p<0.01).

248 The levels of dsDNA in supernatants were significantly increased in sepsis
249 and healthy control neutrophils at 40 mM of ascorbate treatment (1.9 ± 0.95 and 1.8 ±
250 0.9 ng/mL, respectively, n=10), compared to untreated neutrophils (0.94 ± 0.24
251 ng/mL and 0.63 ± 0.14 ng/mL, respectively, n=10, p<0.01) (Figure 4C). In addition,
252 increased levels of *PADI4* mRNA expression were also detected in both groups after
253 their neutrophils were treated with 40 mM of ascorbate (1.04 ± 0.95 and 0.72 ± 0.30,
254 respectively, n=10), compared to untreated neutrophils (p<0.01) (Figure 4D). No
255 significance differences in the levels of dsDNA and *PADI4* mRNA expression
256 between sepsis patients and healthy controls were found at every concentration of
257 ascorbate treatment (p>0.05) (Figure 4C and 4D).

258

259 **4. Discussion**

260 Sepsis is a complex clinical syndrome that develops once a local infection
261 becomes uncontrollable and the causative pathogens invade into the bloodstream,
262 leading to systemic inflammation and multi-organ dysfunction.[13-15] Early clinical
263 diagnosis and prompt treatments are crucial to improve outcomes of patients with
264 sepsis, but the overall mortality rate is tremendously high, particularly in immune-
265 compromised hosts and elderly patients with multiple underlying illnesses.[29-31]

266 In our study, patients were diagnosed with sepsis using the clinical criteria of
267 Sepsis-3. Each patient had both an identified source of infection and an acute change
268 in total SOFA score ≥ 2 points. However, some patients showed unidentified
269 organisms in their hemocultures and this observation was probably because of slow-
270 growing or intracellular organisms, or antibiotic treatment started before blood
271 sampling. [32-34]

272 Neutrophils are the major innate immune cell that play a role in the
273 pathogenesis of sepsis, and previous studies have demonstrated that neutrophil
274 function is dysregulated in these patients.[15] Moreover, ascorbate, an important factor
275 that maintains neutrophil function, rapidly declines in the plasma of neutrophils
276 during sepsis.[10,35-38] In our study, we also found that the plasma level of ascorbate in
277 patients with sepsis was significantly lower than the levels in healthy controls
278 ($p<0.01$) as shown in Table 1. Therefore, it may be hypothesised that ascorbate
279 supplementation could restore impaired neutrophil function in these patients.

280 Our study therefore set out to first determine the function of neutrophils
281 isolated from sepsis patients. Neutrophil chemotaxis is the crucial step in the
282 inflammatory response to invading pathogens and phagocytosis is the main killing
283 mechanism of neutrophils. In our study, chemotaxis and phagocytosis were decreased
284 in patients with sepsis which is consistent with previous studies.[39-42] Furthermore,

285 delayed neutrophil apoptosis is the final step in the cycle of neutrophil activation and
286 the resolution of inflammation,[43] and neutrophils become apoptotic prior to removal
287 by phagocytic cells once they have finished pathogen clearance. However, the rate of
288 neutrophil apoptosis *in vivo* in patients with sepsis is still unknown.[44,45] Our study
289 demonstrated increased spontaneous neutrophil apoptosis 2h post-isolation of
290 neutrophils from patients with sepsis. Our findings support the idea that neutrophil
291 function is abnormal in patients with sepsis and reduced neutrophil migration may be
292 partially due to increased apoptosis.

293 Our next experiments measured the capacity of neutrophils from sepsis
294 patients to undergo spontaneous NETosis. This function is an important killing
295 mechanism of neutrophils against invading pathogens, particularly in the event that
296 extracellular pathogens cannot be appropriately phagocytosed. However,
297 inappropriate NET formation may also contribute to inflammation and autoimmunity,
298 for example by exposure of auto-antigens (eg granule contents) or neo-antigens that
299 are generated via post-translational modification of nuclear proteins (eg citrullinated
300 or acetylated histones).[46] After neutrophil activation, NETs are formed and released
301 extracellularly in order to trap and inhibit systemic spreading of the organisms using
302 the web-like DNA structure. Subsequently, the proteolytic enzymes (eg neutrophil
303 elastase) and myeloperoxidase kill the trapped microbes.[15] The role of NETosis in
304 sepsis is complex in that NET formation may initially help prevent the spread and
305 dissemination of bacteria from a localized site of infection, thereby limiting systemic
306 infection.[47] Nevertheless, excessive NET formation in the later stages of sepsis may
307 play a role in the development of thrombosis and organ failure.[48]

308 In our study, we showed that neutrophils isolated from patients with sepsis
309 developed spontaneous NET formation over a 2h incubation *ex vivo*. This observation
310 is consistent with a previous study, suggesting that neutrophils were already

311 stimulated by the pathogens infecting the patients during sepsis.[49] This finding was
312 confirmed by measurements of an increase in dsDNA levels and upregulation of
313 *PADI4* mRNA expression, a key enzyme involved in the regulation of NETosis,[50] in
314 neutrophils isolated from patients with sepsis. However, we observed a very high
315 range of spontaneous NETosis in these sepsis patients, ranging from 2-3% of the
316 neutrophils to over 80% of the cells undergoing NETosis. These reasons for this very
317 large variation in NETosis are unknown, and we could not find any association
318 between the extent of NETosis and any clinical parameters, tested such as severity of
319 disease, type of bacterial infection, and duration of sepsis or treatment.

320 Therefore, the effect of ascorbate on neutrophil functions were investigated in
321 our study. We found that high concentrations of ascorbate treatment (particularly at
322 40 mM) increased both neutrophil chemotactic and phagocytic activities in these
323 patients. Similar findings have been reported in both sepsis patients and mouse
324 models, which showed increased chemotaxis and phagocytosis after ascorbate
325 supplementation.[11,51,52] Moreover, neutrophil chemotaxis and phagocytosis in healthy
326 controls were increased by ascorbate treatment. Thus, the effects of ascorbate on
327 neutrophil function are not restricted to cells isolated from sepsis patients, but rather
328 are more generalized effects on some neutrophil functions. Interestingly, we noticed
329 that these neutrophil functions were comparable between sepsis patients and healthy
330 controls after their neutrophils were treated with ascorbate (≥ 5 mM), suggesting that
331 neutrophil dysfunction in patients with sepsis were restored and returned to nearly
332 normal function by ascorbate treatment. The potential mechanism of ascorbate on the
333 enhancement of neutrophil chemotaxis and phagocytosis was reported in previous
334 studies which indicated that intracellular microtubule assembly of neutrophil was
335 stabilized by ascorbate treatment, leading to improvement of neutrophil motility and
336 function. [51,53]

337 However, ascorbate treatment did not significantly change the rate of
338 neutrophil apoptosis in our patients and healthy controls. Therefore, this finding
339 suggests that neutrophil apoptosis is still required as the last step of eliminating
340 pathogens in patients with sepsis, and ascorbate is not involved in the apoptotic
341 process of neutrophils. In contrast, a previous study showed that intravenous
342 ascorbate supplementation in patients with sepsis after abdominal surgery temporarily
343 decreased the levels of apoptotic proteins in peripheral blood neutrophils.[54] However,
344 the rate of neutrophil apoptosis was not determined in their study.

345 Having shown that spontaneous NETosis was observed in sepsis patients, we
346 then determined whether ascorbate could alter these levels of NETosis, as serum and
347 plasma levels of ascorbate were shown to be decreased during sepsis in previous
348 studies and our own patients.[37] We found that low level of ascorbate (1mM) could
349 significantly decrease levels of spontaneous NETosis of neutrophils from sepsis
350 patients, which was confirmed by decreased levels of *PADI4* mRNA expression in
351 these patients (Figure 4D). Moreover, we noticed that the levels of NETosis from both
352 sepsis patients and healthy controls were less detectable (<5 NETs counted in Figure
353 4B) and comparable (dsDNA levels in Figure 4C) after their neutrophils were treated
354 with or without 1mM of ascorbate. Our findings suggest that 1 mM of ascorbate
355 treatment significantly reduces spontaneous NET formation in patients with sepsis
356 and their rates of NETosis return to normal as seen in healthy controls. The potential
357 mechanism of ascorbate on decreased NET formation may be due to the modulation
358 of redox-related cell signaling pathways by ascorbate, which stabilizes and protects
359 the cell membrane from oxidative stress during sepsis leading to a decrease in NET
360 release.[51]

361 Higher concentrations of ascorbate (>10 mM) further increased NETosis
362 significantly in both patients with sepsis and healthy controls, above the already high

363 levels observed in the absence of this compound. However, previous studies showed a
364 significant decrease in NETs inside the lungs of ascorbate-deficient mice after
365 ascorbate supplementation,[55,56] which is contrast to our study, and probably explained
366 by different tissue sources of neutrophils studied (lungs VS peripheral blood in our
367 study and species variations) and different concentrations of ascorbate used in both
368 studies.

369 The increased levels of NETosis after higher concentrations of ascorbate
370 treatment was confirmed by measurements of an increase in dsDNA levels in culture
371 supernatants and increased levels of *PADI4* mRNA expression of neutrophils treated
372 with ascorbate. We believe that these higher concentrations of ascorbate further
373 induce an oxidative burst and activate the PAD4 enzyme leading to an increase in
374 NET formation.[57] Nevertheless, the levels of dsDNA at certain concentrations of
375 ascorbate were not significantly different as seen under light microscopy, probably
376 due to some limitations of the PicoGreen assay,[58] and delayed upregulation of mRNA
377 transcription and protien translation which probably need more future studies.

378 As integrin activation is associated with all neutrophil phenotypes observed in
379 our study, we further investigated the activation status of integrins on neutrophils
380 from patients with sepsis and healthy controls as shown in Supplementary Figure 2.
381 As expected, an increase in expression of *ITGB2* (β_2-integrin) was observed in the
382 patient group, probably because their neutrophils were stimulated by pathogens and
383 cytokines during sepsis.[59] However, the *ITGB2* expression was unchanged after
384 ascorbate treatement in both groups.

385 One limitation of this study was that the numbers of isolated neutrophils from
386 patients or healthy controls were varied and sometimes they were not enough to
387 perform every designed experiments. However, these numbers of patients were
388 sufficient for statistical analyses.

389

390 In conclusion, our study demonstrated neutrophil dysfunction in patients with
391 sepsis and ascorbate could improve the defective chemotaxis and phagocytosis
392 observed in neutrophils from these patients. Interestingly, high levels of spontaneous
393 NETosis from sepsis patients could be returned to normal by low concentrations of
394 ascorbate (1 mM). However, further studies are probably needed to investigate the
395 mechanisms how NETosis, chemotaxis and phagocytosis, but not apoptosis, were
396 enhanced by high concentrations of ascorbate, which have never been explored.[51]
397 This study suggests that ascorbate could potentially be used as an adjunctive treatment
398 for patients during sepsis. However, as its effects are highly dose-dependent, such
399 treatments should carefully examine the effective doses that are clinically beneficial
400 and whether NETosis should be prevented or promoted in such patients.

401

402 **Acknowledgements**

403 We would like to thank all patients and healthy controls for their contributions to this
404 study and acknowledge colleagues in the Institute of Integrative Biology, University
405 of Liverpool, Liverpool, UK. Special thanks go to Rachadapisek Sompod Endowment
406 Foundation (RA60/034) and the Faculty of Medicine, Chulalongkorn University,
407 Bangkok, Thailand for financial support.

408

409 **Authorship contributions**

410 All authors made substantial contributions to conception and design, acquisition of
411 data, or analysis and interpretation of data; took part in drafting the article or revising
412 it critically for important intellectual content; gave final approval of the version to be
413 published; and agree to be accountable for all aspects of the work.

414

415 **Conflict of interest disclosures**

416 The author reports no conflicts of interest in this work.

417 ## References

418 1. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation.
419 *Nat Rev Immunol*. 2013;13(3):159-175.
420 2. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. *Nat Rev*
421 *Immunol*. 2018;18(2):134-147.
422 3. Wang Y, Russo TA, Kwon O, Chanock S, Rumsey SC, Levine M. Ascorbate recycling in
423 human neutrophils: induction by bacteria. *Proc Natl Acad Sci U S A*. 1997;94(25):13816-
424 13819.
425 4. Erickson KL, Medina EA, Hubbard NE. Micronutrients and innate immunity. *J Infect Dis*.
426 2000;182 Suppl 1:S5-10.
427 5. Bozonet SM, Carr AC, Pullar JM, Vissers MC. Enhanced human neutrophil vitamin C status,
428 chemotaxis and oxidant generation following dietary supplementation with vitamin C-rich
429 SunGold kiwifruit. *Nutrients*. 2015;7(4):2574-2588.
430 6. Vissers MC, Hampton MB. The role of oxidants and vitamin C on neutrophil apoptosis and
431 clearance. *Biochem Soc Trans*. 2004;32(Pt3):499-501.
432 7. Chatterjee M, Saluja R, Kumar V, et al. Ascorbate sustains neutrophil NOS expression,
433 catalysis, and oxidative burst. *Free Radic Biol Med*. 2008;45(8):1084-1093.
434 8. Chambial S, Dwivedi S, Shukla KK, John PJ, Sharma P. Vitamin C in disease prevention and
435 cure: an overview. *Indian J Clin Biochem*. 2013;28(4):314-328.
436 9. Figueroa-Mendez R, Rivas-Arancibia S. Vitamin C in Health and Disease: Its Role in the
437 Metabolism of Cells and Redox State in the Brain. *Front Physiol*. 2015;6:397.
438 10. Anderson R, Oosthuizen R, Maritz R, Theron A, Van Rensburg AJ. The effects of increasing
439 weekly doses of ascorbate on certain cellular and humoral immune functions in normal
440 volunteers. *Am J Clin Nutr*. 1980;33(1):71-76.
441 11. de la Fuente M, Ferrandez MD, Burgos MS, Soler A, Prieto A, Miquel J. Immune function in
442 aged women is improved by ingestion of vitamins C and E. *Can J Physiol Pharmacol*.
443 1998;76(4):373-380.
444 12. Mohammed BM, Fisher BJ, Kraskauskas D, et al. Vitamin C: a novel regulator of neutrophil
445 extracellular trap formation. *Nutrients*. 2013;5(8):3131-3151.
446 13. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. *Lancet*.
447 2013;381(9868):774-775.
448 14. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med*.
449 2003;348(2):138-150.
450 15. Shen XF, Cao K, Jiang JP, Guan WX, Du JF. Neutrophil dysregulation during sepsis: an
451 overview and update. *J Cell Mol Med*. 2017;21(9):1687-1697.
452 16. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
453 Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama-Journal of the American Medical*
454 *Association*. 2016;315(8):801-810.
455 17. Kaukonen KM, Bailey M, Bellomo R. Systemic Inflammatory Response Syndrome Criteria
456 for Severe Sepsis. *N Engl J Med*. 2015;373(9):881.
457 18. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis For the
458 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama-*
459 *Journal of the American Medical Association*. 2016;315(8):762-774.
460 19. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
461 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-810.
462 20. Chiewchengchol D, Wright HL, Thomas HB, et al. Differential changes in gene expression in
463 human neutrophils following TNF-alpha stimulation: Up-regulation of anti-apoptotic proteins
464 and down-regulation of proteins involved in death receptor signaling. *Immun Inflamm Dis*.
465 2016;4(1):35-44.
466 21. Chiewchengchol D, Midgley A, Sodsai P, et al. The protective effect of GM-CSF on serum-
467 induced neutrophil apoptosis in juvenile systemic lupus erythematosus patients. *Clin*
468 *Rheumatol*. 2015;34(1):85-91.

469 22. Ballantine L, Midgley A, Harris D, Richards E, Burgess S, Beresford MW. Increased soluble
470 phagocytic receptors sMer, sTyro3 and sAxl and reduced phagocytosis in juvenile-onset
471 systemic lupus erythematosus. *Pediatr Rheumatol Online J*. 2015;13:10.
472 23. Wlodkowic D, Skommer J, Darzynkiewicz Z. Flow cytometry-based apoptosis detection.
473 *Methods Mol Biol*. 2009;559:19-32.
474 24. Wright HL, Makki FA, Moots RJ, Edwards SW. Low-density granulocytes: functionally
475 distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective
476 TNF signalling. *J Leukoc Biol*. 2017;101(2):599-611.
477 25. Dong S, Zhang Z, Takahara H. Estrogen-enhanced peptidylarginine deiminase type IV gene
478 (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-alpha-promoted
479 transfactors activator protein-1, nuclear factor-Y, and Sp1. *Mol Endocrinol*. 2007;21(7):1617-
480 1629.
481 26. Margraf S, Logters T, Reipen J, Altrichter J, Scholz M, Windolf J. Neutrophil-derived
482 circulating free DNA (cf-DNA/NETs): a potential prognostic marker for posttraumatic
483 development of inflammatory second hit and sepsis. *Shock*. 2008;30(4):352-358.
484 27. Lee KH, Cavanaugh L, Leung H, et al. Quantification of NETs-associated markers by flow
485 cytometry and serum assays in patients with thrombosis and sepsis. *Int J Lab Hematol*.
486 2018;40(4):392-399.
487 28. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria.
488 *Science*. 2004;303(5663):1532-1535.
489 29. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology
490 of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of
491 care. *Crit Care Med*. 2001;29(7):1303-1310.
492 30. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to reconsider the concept. *Crit
493 Care Med*. 2008;36(3):964-966.
494 31. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. *J Clin Invest*. 2003;112(4):460-
495 467.
496 32. Pilecky M, Schildberger A, Orth-Holler D, Weber V. Pathogen enrichment from human whole
497 blood for the diagnosis of bloodstream infection: Prospects and limitations. *Diagn Microbiol
498 Infect Dis*. 2019;94(1):7-14.
499 33. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition,
500 pathophysiology, and management. *SAGE Open Med*. 2019;7:2050312119835043.
501 34. Horak J, Martinkova V, Radej J, Matejovic M. Back to Basics: Recognition of Sepsis with
502 New Definition. *J Clin Med*. 2019;8(11).
503 35. Galley HF, Davies MJ, Webster NR. Ascorbyl radical formation in patients with sepsis: effect
504 of ascorbate loading. *Free Radic Biol Med*. 1996;20(1):139-143.
505 36. Spoelstra-de Man AME, Elbers PWG, Oudemans-Van Straaten HM. Vitamin C: should we
506 supplement? *Curr Opin Crit Care*. 2018;24(4):248-255.
507 37. Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C
508 and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral
509 intakes. *Crit Care*. 2017;21(1):300.
510 38. Long CL, Maull KI, Krishnan RS, et al. Ascorbic acid dynamics in the seriously ill and
511 injured. *J Surg Res*. 2003;109(2):144-148.
512 39. Lerman YV, Kim M. Neutrophil migration under normal and sepsis conditions. *Cardiovasc
513 Hematol Disord Drug Targets*. 2015;15(1):19-28.
514 40. Arraes SM, Freitas MS, da Silva SV, et al. Impaired neutrophil chemotaxis in sepsis
515 associates with GRK expression and inhibition of actin assembly and tyrosine
516 phosphorylation. *Blood*. 2006;108(9):2906-2913.
517 41. Alves-Filho JC, de Freitas A, Russo M, Cunha FQ. Toll-like receptor 4 signaling leads to
518 neutrophil migration impairment in polymicrobial sepsis. *Crit Care Med*. 2006;34(2):461-470.
519 42. Taneja R, Sharma AP, Hallett MB, Findlay GP, Morris MR. Immature circulating neutrophils
520 in sepsis have impaired phagocytosis and calcium signaling. *Shock*. 2008;30(6):618-622.
521 43. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid
522 arthritis. *Nat Rev Rheumatol*. 2014;10(10):593-601.
523 44. Taneja R, Parodo J, Jia SH, Kapus A, Rotstein OD, Marshall JC. Delayed neutrophil apoptosis
524 in sepsis is associated with maintenance of mitochondrial transmembrane potential and
525 reduced caspase-9 activity. *Crit Care Med*. 2004;32(7):1460-1469.
526 45. Keel M, Ungethum U, Steckholzer U, et al. Interleukin-10 counterregulates proinflammatory
527 cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. *Blood*.
528 1997;90(9):3356-3363.

529 46. Chapman EA, Lyon M, Simpson D, et al. Caught in a Trap? Proteomic Analysis of Neutrophil
530 Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus. *Front*
531 *Immunol*. 2019;10:423.
532 47. O'Brien XM, Biron BM, Reichner JS. Consequences of extracellular trap formation in sepsis.
533 *Curr Opin Hematol*. 2017;24(1):66-71.
534 48. Li RHL, Tablin F. A Comparative Review of Neutrophil Extracellular Traps in Sepsis. *Front*
535 *Vet Sci*. 2018;5:291.
536 49. Gavillet M, Martinod K, Renella R, et al. Flow cytometric assay for direct quantification of
537 neutrophil extracellular traps in blood samples. *Am J Hematol*. 2015;90(12):1155-1158.
538 50. Rohrbach AS, Slade DJ, Thompson PR, Mowen KA. Activation of PAD4 in NET formation.
539 *Front Immunol*. 2012;3:360.
540 51. Carr AC, Maggini S. Vitamin C and Immune Function. *Nutrients*. 2017;9(11).
541 52. Goldschmidt MC, Masin WJ, Brown LR, Wyde PR. The effect of ascorbic acid deficiency on
542 leukocyte phagocytosis and killing of actinomyces viscosus. *Int J Vitam Nutr Res*.
543 1988;58(3):326-334.
544 53. Parker WH, Rhea EM, Qu ZC, Hecker MR, May JM. Intracellular ascorbate tightens the
545 endothelial permeability barrier through Epac1 and the tubulin cytoskeleton. *Am J Physiol*
546 *Cell Physiol*. 2016;311(4):C652-C662.
547 54. Ferron-Celma I, Mansilla A, Hassan L, et al. Effect of vitamin C administration on neutrophil
548 apoptosis in septic patients after abdominal surgery. *J Surg Res*. 2009;153(2):224-230.
549 55. Fisher BJ, Seropian IM, Kraskauskas D, et al. Ascorbic acid attenuates lipopolysaccharide-
550 induced acute lung injury. *Crit Care Med*. 2011;39(6):1454-1460.
551 56. Fisher BJ, Kraskauskas D, Martin EJ, et al. Attenuation of sepsis-induced organ injury in mice
552 by vitamin C. *JPEN J Parenter Enteral Nutr*. 2014;38(7):825-839.
553 57. Liugan M, Carr AC. Vitamin C and Neutrophil Function: Findings from Randomized
554 Controlled Trials. *Nutrients*. 2019;11(9).
555 58. Koba M, Szostek A, Konopa J. Limitation of usage of PicoGreen dye in quantitative assays of
556 double-stranded DNA in the presence of intercalating compounds. *Acta Biochim Pol*.
557 2007;54(4):883-886.
558 59. Langereis JD. Neutrophil integrin affinity regulation in adhesion, migration, and bacterial
559 clearance. *Cell Adh Migr*. 2013;7(6):476-481.

560

561

562

563

564

565

566

567

568

569



570
571
572 **Figure 1.** Representative images of neutrophils from cell migration stained with
573 trypan blue and counted by automated cell counter (A), and the percentages of
574 neutrophil chemotaxis of healthy donors (n=10) and patients with sepsis (n=10) (B).
575 Representative flow cytometry results (C), and the percentages of phagocytic activity
576 of healthy donors (n=5) and patients with sepsis (n=5) (D). Representative flow
577 cytometry results (E), and the percentages of neutrophil apoptosis of healthy donors
578 (n=5) and patients with sepsis (n=5) (F). (**; p<0.01, ***; p<0.005).
579
580
581
582
583
584
585
586
587
588
589
590
591



592
593 **Figure 2.** Representative fluorescence images (400X) of isolated neutrophils from
594 healthy controls (n=20) and patients with sepsis (n=20), stained with DAPI (blue),
595 elastase (green) and myeloperoxidase (red), and merged images for NET
596 identification after 2h post-isolation *ex vivo* (A). Spontaneous NET formation after 2h
597 post-isolation (B), the levels of dsDNA (C) and *PADI4* mRNA expression (D) from
598 healthy controls and patients with sepsis (n=10 for both groups), (*; $p<0.05$, **;
599 $p<0.01$, ****; $p<0.001$).
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622



623
624
625 **Figure 3.** The percentages of neutrophil chemotaxis or cell migration (A), phagocytosis (B) and apoptosis (C) from healthy donors and patients with sepsis (n=5 for both groups) and the effect of ascorbate (1, 5, 10, 20 and 40 mM) on neutrophils after 2h treatment. (**** p< 0.0001, *** p< 0.001, ** p< 0.01, * p< 0.05) ($^{##}$; p<0.01, $^{###}$; p<0.005, $^{####}$; p<0.001; when compared between groups).
630
631
632



633
634 **Figure 4.** Effect of ascorbate on NET formation. Representative fluorescence images (400X) of isolated neutrophils from patients with sepsis and healthy controls treated with 1, 10 and 40 mM of ascorbate for 2h and stained with DAPI staining for NET identification (A). NETs counted per 100 neutrophils (n=20 for both groups) (B), the levels of dsDNA (C) and *PADI4* mRNA expression (D) from patients with sepsis and healthy controls (n=10 for both groups) treated with different concentrations of ascorbate (1, 5, 10, 20 and 40 mM) for 2h (**** p< 0.0001, *** p< 0.001, ** p< 0.01) ($^{##}$; p<0.01, $^{####}$; p<0.001; when compared between groups).
642
643
644
645
646



647
648 **Supplementary Figure 1.** Effect of phorbol myristate acetate (PMA; 600nM) on
649 NET formation. NETs counted per 100 neutrophils (n=5 for both groups) (A), the
650 levels of dsDNA (B) from patients with sepsis and healthy controls (n=5 for both
651 groups) (**** $p < 0.0001$, *** $p < 0.001$).
652
653
654
655



656
657 **Supplementary Figure 2.** The *ITGB2* mRNA expression (A) of isolated neutrophils
658 from patients with sepsis and healthy controls (n=5 for both groups), and (B) cells
659 treated with different concentrations of ascorbate (1, 5, 10, 20 and 40 mM) for 2h (*
660 $p < 0.05$).
661
662
663

664 **Table 1**. Demographic data

Characteristic	Healthy (N=20)	Sepsis (N=20)	*p*-value
Gender			
-male (%)	11 (55)	11 (55)	1.0
-female (%)	9 (45)	9 (45)	1.0
Mean age, years ± SD	61 ± 14.1	60 ± 12.2	1.0
Time of diagnosis: days after hospitalization; Median (IQ range)	N/A	11 (6 - 28)	N/A
WBC count (x10^3cells/µL ± SD)	6.7 ± 2.3	16.5 ± 9.6	<0.001
-Absolute neutrophil (x10^3cells/µL ± SD)	4.1 ± 2.0	14.3 ± 9.4	<0.001
Underlying illnesses			
- Diabetes mellitus, n (%)	6 (30)	5 (25)	>0.99
- Hypertension, n (%)	6 (30)	7 (35)	>0.99
- Ischemic heart disease, n (%)	0 (0)	2 (10)	0.49
- Dyslipidemia, n (%)	3 (15)	1 (5)	0.61
- Malignancy, n (%)	0 (0)	8 (40)	0.003
Organisms (identified in blood)			
- *Staphylococcus* spp.	N/A	1 (5)	N/A
- *Escherichia* spp.	N/A	2 (10)	N/A
- *Candida* spp.	N/A	2 (10)	N/A
- unidentified organisms	N/A	15 (75)	N/A
Plasma level of ascorbate or vitamin C (mg/L ± SD)	7.79 ± 3.86	1.03 ± 2.07	<0.01

Abbreviations: SD; standard deviation, WBC; white blood cell, N/A; not applicable

665

666 Supplementary Table 1. Detailed information of patients with sepsis
667

Patient No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Gender	M	F	F	F	F	F	F	M	F	M	M	M	M	M	M	F	F	M	M	M
Age	65	65	60	27	63	34	66	64	61	60	65	60	39	60	67	70	72	62	63	78
Source of infection	GI tract	GI tract	GI tract	RS	GI tract	GI tract	RS	RS	Skin	Skin	RS	GI tract	CNS	GU tract	RS	RS	RS	RS	Skin	GI Tract
BUN (mg/dL)	52	91	18	9	51	15	14	44	56	62	71	34	91	102	20	64	2.26	1.18	0.72	51
Cr (mg/dL)	3.52	5.01	0.71	0.72	2.03	1.96	1.69	2.15	1.54	1.28	2.12	2.95	3.7	3.08	1.82	3.49	21.5	66.5	109.81	3.54
TB (mg/dL)	0.43	0.6	0.87	NA	33.52	1.64	0.74	0.51	0.72	2.19	0.47	12.55	3.16	16.41	0.65	0.74	0.29	1.39	1.42	0.84
DB (mg/dL)	0.33	0.49	0.61	NA	23.68	0.82	0.41	0.38	0.32	1.71	0.19	8.2	2.51	11.18	0.29	0.53	51	71	47	0.55
SGOT (U/L)	31	50	46	NA	14	1417	2199	33	87	36	29	1590	155	103	55	29	41	32	52	49
SGPT (U/L)	34	56	70	NA	2	632	1047	29	87	27	33	816	139	8	14	13	74	168	36	26
ALP (U/L)	265	452	372	NA	147	72	95	90	68	94	123	443	157	384	244	72	140	141	135	117
Na (mmol/L)	137	141	146	134	138	148	133	131	141	143	145	134	143	132	133	142	4.3	3.5	3.1	146
K (mmol/L)	3.5	4.3	3.5	3.5	3.1	3.9	4	5	4	3.8	4.3	3.3	4.6	4.8	3.5	3.5	106	116	109	3.6
Cl (mmol/L)	108	107	111	106	96	95	87	95	101	112	110	98	113	96	102	102	25	11	18	106
CO_2 (mmol/L)	17	17	15	21	18	17	23	24	20	19	21	22	19	13	17	21	235	78	7	19
Platelet (10^3/uL)	299	234	55	286	82	95	204	230	146	39	117	61	558	43	140	284	8.25	18.18	0.19	55
SOFA score	11	13	12	5	16	11	9	4	2	8	10	18	10	15	10	4	10	8	8	12

668 **Abbreviations**: GI; gastrointestinal, RS; respiratory system, CNS; central nervous system, GU; genitourinary, and SOFA; Sequential Sepsis-Related
669 Organ Failure Assessment, SD; standard deviation, N/A; not applicable